Patents by Examiner Mary E. Mosher
  • Patent number: 9463237
    Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: October 11, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Falko-G√ľnter Falkner, Birgit Schafer, P. Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
  • Patent number: 9241998
    Abstract: The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: January 26, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Santanu Bose, Bandana Chatterjee
  • Patent number: 9220769
    Abstract: The present invention provides a modified influenza virus wherein the RNA of the haemagglutinin gene has been modified such that the haemagglutinin signal sequence is not expressed and the virus produces a haemagglutinin protein that lacks a functional signal sequence. The invention further provides composition comprising the modified virus and uses of the modified virus.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: December 29, 2015
    Assignee: Isis Innovation, Ltd.
    Inventor: Alain Townsend
  • Patent number: 9216212
    Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: December 22, 2015
    Assignee: University of Massachusetts
    Inventor: Trudy Morrison
  • Patent number: 9212349
    Abstract: A method for improving virus production in a host cell infected with the virus is provided.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: December 15, 2015
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas Shenk, Emre Koyuncu, Joshua D. Rabinowitz
  • Patent number: 9205065
    Abstract: A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
    Type: Grant
    Filed: April 19, 2015
    Date of Patent: December 8, 2015
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Hugh McTavish, Thomas Dag Horn, Sandra Marchese Johnson
  • Patent number: 9205145
    Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: December 8, 2015
    Assignee: Zoetis Services LLC
    Inventor: Joan Plana Duran
  • Patent number: 9200259
    Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: December 1, 2015
    Inventors: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia
  • Patent number: 9200042
    Abstract: Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: December 1, 2015
    Assignee: VaxInnate Corporation
    Inventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
  • Patent number: 9194873
    Abstract: The present invention generally relates to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a test sample.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: November 24, 2015
    Assignee: ABBOTT LABORATORIES
    Inventors: George J. Dawson, Suresh M. Desai, Robin A. Gutierrez, A. Scott Muerhoff, John Prostko
  • Patent number: 9181328
    Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 10, 2015
    Assignees: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCES MINISTRY OF PUBLIC HEALTH
    Inventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
  • Patent number: 9180181
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: November 10, 2015
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 9180180
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: November 10, 2015
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 9180179
    Abstract: We have generated novel molecularly marked FMDV A24LL3DYR and A24LL3BPVKV3DYR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3Dpol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A24LL3DYR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: November 10, 2015
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Aida E. Rieder, Luis L. Rodriguez, Jason R. Hollister, Sabena Uddowla
  • Patent number: 9180150
    Abstract: A poxvirus comprising a defective F2L gene and compositions comprising such poxvirus are useful for therapeutic purposes, and more particularly for the treatment of cancer.
    Type: Grant
    Filed: November 17, 2008
    Date of Patent: November 10, 2015
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Johann Foloppe
  • Patent number: 9175069
    Abstract: Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: November 3, 2015
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Taia T. Wang
  • Patent number: 9169297
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: October 27, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • Patent number: 9169465
    Abstract: Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: October 27, 2015
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Federico A. Zuckermann
  • Patent number: 9163068
    Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: October 20, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 9157915
    Abstract: The present invention discloses specific human metapneumovirus monoclonal antibodies. The antibody is at least two-fold less reactive with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Further, the antibody is at least two-fold more reactive with a human metapneumovirus (i.e., for example, Type A or Type B) than with non-human metapneumoviruses including, but not limited to, respiratory viruses or avian metapneumoviruses. Consequently, these novel antibodies are useful as a clinical diagnostic agent, especially when using fresh nasopharengeal aspirates. The invention also contemplates numerous diagnostic platforms that together with the novel antibodies can support economical, fast, and highly selective detection and identification of clinical inoculum samples.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: October 13, 2015
    Assignee: DIAGNOSTIC HYBRIDS, INC.
    Inventors: Giuseppe Gerna, Antonella Sarasini, Maria Grazia Revello